Recent Quotes (30 days)

You have no recent quotes
chg | %

Roche Holding Ltd. (ADR)  

(Public, OTCMKTS:RHHBY)   Watch this stock  
Find more results for PINK:RHHBY
31.57
-0.15 (-0.47%)
After Hours: 31.57 0.00 (0.00%)
Apr 29, 5:20PM EDT  
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 31.00 - 31.71
52 week 29.89 - 38.54
Open 31.68
Vol / Avg. 789,059.00/1.00M
Mkt cap 216.74B
P/E 23.74
Div/yield 1.02/3.22
EPS 1.33
Shares 692.02M
Beta 0.74
Inst. own 16%
Jul 21, 2016
Half Year 2016 Roche Holding AG Earnings Release - 1:00AM EDT - Add to calendar
Jun 23, 2016
Roche Holding AG at JPMorgan European Healthcare Conference Add to calendar
Jun 22, 2016
Roche Holding AG at Citi European Healthcare Conference Add to calendar
Jun 16, 2016
Roche Holding AG at Exane CEO Seminar Add to calendar
Jun 10, 2016
Roche Holding AG at Barclays�European�Select�Conference Add to calendar
Jun 9, 2016
Roche Holding AG at Goldman Sachs Global Healthcare Conference Add to calendar
Jun 8, 2016
Roche Holding AG at Deutsche Bank dbAccess German, Swiss & Austrian Conference Add to calendar
Jun 8, 2016
Roche Holding AG at Vontobel Summer Conference Add to calendar
Jun 7, 2016
Roche Holding AG at Jefferies Healthcare Conference Add to calendar
Jun 5, 2016
Roche Holding AG Analyst Event at ASCO 2016 - 8:30PM EDT - Add to calendar
  

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 15.50% 18.81%
Operating margin 23.30% 27.89%
EBITD margin - 40.92%
Return on average assets 10.50% 11.97%
Return on average equity 38.85% 43.70%
Employees 91,747 -
CDP Score - 100 A

Address

Grenzacherstr. 124
BASEL, 4058
Switzerland
+41-9-732354295 (Phone)

Website links

External links

Description

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Company's Pharmaceuticals Division comprises the two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Europe, the Middle East and Africa (EMEA), and Japan. The Company focuses on a select group of disease areas, including oncology, hematology, neuroscience, immunology, inflammation, ophthalmology, infectious and rare diseases. Its key pharmaceutical products include Avastin, Herceptin, Perjeta, Kadcyla, MabThera/Rituxan, Lucentis, Actemra/RoActemra, Zelboraf and Gazyva/Gazyvaro.

Officers and directors

Severin Schwan Chairman of the Corporate Executive Committee, Chief Executive Officer, Director
Age: 49
Alan Hippe Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer
Age: 49
Stephan Feldhaus Member of the Enlarged Corporate Executive Committee, Head Group Communications
Age: 54
Sophie Kornowski-Bonnet Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering
Age: 52
Osamu Nagayama Member of the Enlarged Corporate Executive Committee, President and Chief Executive Officer of Chugai
Age: 68
John C. Reed M.D., Ph.D. Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
Age: 58
Michael David Varney Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
Age: 58
Urs Jaisli Chief Compliance Officer
Age: 60
Gottlieb A. Keller Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors
Age: 62
Silvia Ayyoubi Member of the Corporate Executive Committee, Head Group Human Resources
Age: 63